Charles River Laboratories International Inc
Change company Symbol lookup
Select an option...
CRL Charles River Laboratories International Inc
PXSAP Pyxis Tankers Inc
DNUT Krispy Kreme Inc
SDGR Schrodinger Inc
BOAS BOA Acquisition Corp
ESBA Empire State Realty OP LP
ASGN ASGN Inc
CMS CMS Energy Corp
POWRU Powered Brands
VLDRW Velodyne Lidar Equity Warrants Exp 29 Sep 2025 *W EXP 09/29/2025
Go

Health Care : Life Sciences Tools & Services | Mid Cap Growth
Company profile

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company provides products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions in research and drug development. The Company operates through two segments: Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing). The DSA segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions, and Avian Vaccine Services.

Premarket

Last Trade
Delayed
$312.32
0.08 (0.03%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$312.24
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
13

10-day average volume:
435,707
13

CRL's position in the Life Sciences Tools & Services industry

Industry PeersCRLIQVSYNHMEDP

Summary

Company ProfileCharles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company provides products and services to help pharmaceutical and biotechnology companies...
IQVIA Holdings Inc. is a provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company’s segments include Technology & Analytics...
Go to IQV summary
Syneos Health, Inc. is a biopharmaceutical solutions company. The Company provides a range of clinical and commercial services to customers in the pharmaceutical, biotechnology, and healthcare...
Go to SYNH summary
Medpace Holdings, Inc. is a provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in...
Go to MEDP summary
52-Week Change

VS. INDUSTRY
19.69%
29.86%
12.66%
23.38%
Market Cap

VS. INDUSTRY
$15.8B
$44.3B
$8.9B
$5.9B
Beta

VS. INDUSTRY
1.2
1.5
1.8
1.4
Dividend Yield

VS. INDUSTRY
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
40.43x
59.01x
35.81x
34.19x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$3.4B
$13.5B
$5.0B
$1.1B
Profit Margin

VS. INDUSTRY
11.77%
5.76%
5.04%
16.71%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
17.94%
-14.23%
-1.24%
--
Revenue Growth (TTM)

VS. INDUSTRY
21.32%
23.55%
10.94%
22.02%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.